Anti-integrin antibodies are disclosed. Also disclosed are methods of using the antibodies to treat or prevent disorders such as fibrotic diseases, cancer, ophthalmology disorders, and NAFLD. Further disclosed are methods of selecting an antibody that specifically binds to αvβ{umlaut over (í)}, or that binds to αvβ{umlaut over (í)} and αvβó, or that binds to one or more members of the RGD sub-family of integrins.